Delian Capital
VC Fund
Beijing, China
Delian Capital is a VC fund in Beijing focused on Biotechnology and Health Care. Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.
- Total investments:
- 97
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries Delian Capital invests in
Stages Delian Capital invests in
Countries Delian Capital invests in
Round sizes
Contacts
3 more contacts available
Round size
- Seed
- $1.5M–$50M
- Series A
- $1.6M–$19M
- Series B
- $9.9M–$29M
Investment Focus
Industry
- Biotechnology 22 (23%)
- Health Care 18 (19%)
- Manufacturing 18 (19%)
- Medical 12 (12%)
- Biopharma 10 (10%)
Stage
- Series A 30 (31%)
- Seed 26 (27%)
- Series B 12 (12%)
- Angel 9 (9%)
- Series C 7 (7%)
Country
- China 70 (72%)
- United States 11 (11%)
- France 1 (1%)
- Hong Kong 1 (1%)
- Singapore 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Fang Hong
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Quan Li
Founding Partner
|
Founding Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BCI-Sonics
|
BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications. | $14.8M / Angel / Jun 08, 2026 | |
Gnosis Healthineer
|
Gnosis Healthineer provides medical devices to hospitals such as Clinical EEG AI Model. It builds an EEG data center for second- and third-level general hospitals to solve the problem of insufficient EEG data storage. The hardware construction of the data center includes: PB-level storage and servers, and high-performance computing equipment. | $14.8M / Series A / Jun 05, 2026 | |
Genrobot.ai
|
Genrobot.ai develops AI-powered robots for automation, data analysis, and intelligent task management across industries. | Seed / Jun 01, 2026 | |
|
Junhe Atom
|
Junhe Atom is a company that focuses on Small modular nuclear reactors. | Angel / May 22, 2026 | |
MingShi Brain-Computer Interaction
|
Mindtrix (明视脑机) develops brain–computer‑interface technology focused on reconstructing visual information and neural signals from the brain, primarily for visual‑reconstruction and implantable‑BCI applications. It conducts research and builds systems to decode brain‑wave patterns and translate them into machine‑interpretable outputs, aiming atadvanced neurotechnology and human–machine interfaces. The company also works on underlying hardware and software platforms that support high‑precision neural data acquisition, processing, and real‑time feedback loops. | $21.8M / Angel / Apr 02, 2026 | |
Rigerna
|
Rigerna develops unique small nucleic acid medicines and innovative nucleic acid therapies for nonliver tissues. | $29M / Seed / Mar 20, 2026 | |
Neowise
|
XinjingZhiyuan is an immune cell therapy company focusing on solid tumors. | $28.7M / Series B / Jan 26, 2026 | |
|
Neowise
|
XinjingZhiyuan is an immune cell therapy company focusing on solid tumors. | $28.7M / Series B / Jan 26, 2026 | |
Zendure
|
Zendure specialized in research, development, and sale of residential energy storage and energy management systems. It focuses on the development of fields including industrial design, structure, software, and hardware. | Series B / Dec 31, 2025 | |
Lingke Medical
|
Lingke Medical is a company specializing in intelligent temperature-controlled therapy technology, dedicated to developing innovative medical solutions that integrate advanced sensing, precise thermal regulation, and smart control systems to improve treatment effectiveness, patient comfort, and clinical outcomes across a range of healthcareapplications. | Series A / Dec 15, 2025 | |
| See all 97 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Delian Capital invest in?
Delian Capital invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series A and Seed stage. Most of the 97 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Delian Capital's check size?
Delian Capital typically joins rounds of $1.5M–$50M at Seed, $1.6M–$19M at Series A and $9.9M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Delian Capital participates in.
How do I contact Delian Capital?
Public channels for Delian Capital include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Delian Capital?
The team at Delian Capital includes Fang Hong (Managing Director) and Quan Li (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
